CPT 87230 Reimbursement & Policy Benchmarks

CPT code 87230 describes a laboratory cytotoxicity assay used to detect toxins or poisons produced by specific organisms (for example, Clostridium difficile) using cell or tissue culture. This test is clinically important because it directly identifies biologically active toxin, which can confirm toxin-mediated disease and guide clinical management. Nationally, accurate coding and coverage for toxin assays affect laboratory workflow, hospital diagnostic pathways, and public health surveillance.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for cytotoxicity-based toxin testing, typical sites of service, and the common modifiers associated with lab billing. The publication outlines what to expect in payer coverage policies, coding considerations for laboratory reporting, and benchmark topics relevant to utilization and reimbursement practice.

The report also summarizes common operational implications for laboratories that perform culture-based toxin assays, including equipment and staffing needs inherent to cell/tissue culture testing. Data not available in the input will be noted where applicable. The focus is national policy and billing context rather than state-level specifics.

Billing Code Overview

CPT code 87230 describes a laboratory assay in which a lab analyst tests for a toxin or poison produced by a specific organism, for example toxins from Clostridium difficile, using cell or tissue culture methods. The procedure is a laboratory diagnostic test that detects biologically active toxins through cytotoxicity assays performed on cultured cells.

Service type: Laboratory diagnostic assay (toxin detection via cell/tissue culture)

Typical site of service: Clinical laboratory or hospital laboratory setting where cell or tissue culture and cytotoxicity testing can be performed.

Clinical Context

A 68-year-old hospitalized patient with antibiotic-associated diarrhea and new-onset leukocytosis is suspected of having Clostridioides difficile infection (CDI). The attending physician orders diagnostic tests to detect C. difficile toxin. A specimen of stool is collected and sent to the microbiology laboratory. The lab technologist performs a cell culture cytotoxicity neutralization assay (CCNA) — documented by 87230 — to detect toxin-mediated cytopathic effect on tissue culture cells. The workflow includes specimen receipt, verification, preparation of stool filtrate, inoculation onto cell monolayers, incubation with and without specific antitoxin, microscopic evaluation for cytopathic effect, and documentation of results in the laboratory information system. Results guide infection control, antimicrobial therapy decisions, and isolation precautions.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when reporting only the professional interpretation or participation by the pathologist/microbiologist separate from the laboratory technical component.
`TC`	Technical component

Taxonomy Code	Specialty	Notes
`0000C0300X`	Clinical Pathology / Microbiology	Medical directors and laboratorians who interpret toxin assays.
`0000S0200X`	Infectious Disease	Clinicians ordering and applying results for treatment of toxin-mediated infections.
`000000000X`	Hospitalist	Physicians coordinating inpatient diagnostic testing and management.
`363L00000X`	Medical Laboratory Technologist/Technician	Personnel performing the cell culture assay and technical processes.
`207H00000X`	General Surgery	Surgical clinicians occasionally involved when surgical specimens or operative stool sampling are required.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`A04.7`	Enterocolitis due to Clostridium difficile	Primary indication for performing a C. difficile toxin assay by cell culture.
`R19.7`	Diarrhea, unspecified	Common presenting symptom prompting stool testing for toxin-producing organisms.
`A09`	Infectious gastroenteritis and colitis, unspecified	Broad diagnosis category; toxin testing helps identify specific causative organism.
`A41.9`	Sepsis, unspecified organism	In severe cases with systemic signs, stool toxin testing can be part of the infectious workup.
`K52.2`	Toxic gastroenteritis and colitis	When toxin-mediated injury is suspected, assays for microbial toxins are relevant.
`B96.20`	Unspecified intestinal infection due to Clostridium difficile	Used as a secondary code to identify C. difficile as the causative agent when toxin is confirmed.
`Z86.19`	Personal history of other infectious and parasitic diseases	Relevant for documenting recurrence risk and clinical history when interpreting repeat toxin assays.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`87045`	Culture, bacterial; stool, continuous culture for enteric pathogens	Performed when culture-based detection of bacterial enteric pathogens is indicated alongside toxin testing.
`87493`	Infectious agent detection by nucleic acid (DNA or RNA); C. difficile, direct probe technique (eg, hybridization)	Alternative molecular diagnostic performed for direct detection of C. difficile toxin genes or organism; often ordered concurrently or instead of cytotoxicity assays.
`87498`	Infectious agent detection by nucleic acid (DNA or RNA); multiple organisms (multiplex)	Used when a multiplex panel for enteric pathogens is ordered in the same clinical workup for diarrhea.
`87086`	Culture, bacterial; urine, for screening and identification	Example of culture workup codes used in parallel laboratory workflows when multiple specimen types are processed (urine vs stool) — indicates laboratory procedural context.
`87070`	Culture, fungal; any other source except blood	May be used when fungal testing is considered in an immunocompromised patient with gastrointestinal symptoms.

OpenPayer

Summary & Overview

CPT 87230: Toxin Detection by Cell or Tissue Culture Assay